Legal Status Overview
Gray AreaArkansas has no statute or Board of Pharmacy rule that names peptides or 'research chemicals' as a distinct legal category; instead, peptide legality in Arkansas is governed by the same general pharmacy-licensing and compounding framework that applies to all drugs. The Arkansas State Board of Pharmacy regulates compounding under its Good Compounding Practices rule and recently updated its compounding rules (Act 961 of 2025) to address 503B-to-503A sales, layered on top of the federal FDA 503A/503B compounding framework. Unapproved peptides like BPC-157 and TB-500 are not FDA-approved drugs and cannot legally be prescribed, compounded, or sold for human use in Arkansas, though an FDA advisory panel in mid-2026 recommended several of these peptides for the 503A bulk substances list, which could change their status if finalized.
Key Points
- Arkansas has no peptide-specific or 'research chemical'-specific statute or Board of Pharmacy regulation; peptides fall under the state's general pharmacy licensing and compounding law. [4]
- Under Arkansas law, it is unlawful for anyone other than a licensed pharmacist to compound or dispense a prescription drug, which applies equally to prescription-only peptides like semaglutide and tirzepatide. [4]
- The Arkansas State Board of Pharmacy's Good Compounding Practices rule (070.00.01 Ark. Code R. 001) sets the minimum standards that any Arkansas pharmacy must follow when compounding a peptide-containing drug product. [5]
- Arkansas Act 961 of 2025 prompted 2026 Board of Pharmacy rule updates governing 503B-to-503A sales and sterile compounding standards, meaning compounded peptide products obtained from 503B outsourcing facilities must be resold through Arkansas retail pharmacies under newly specified conditions. [3]
- BPC-157 is classified federally as an unapproved drug that cannot be legally prescribed or sold over the counter anywhere in the U.S., including Arkansas, because it does not appear in the FDA's approved drugs database. [2]
- A person in Arkansas can legally bring in or buy a peptide like semaglutide, tirzepatide, or physician-prescribed HGH only with a valid prescription dispensed through a state-licensed pharmacy; unapproved 'research-use-only' peptides are not legal for personal human use regardless of how they are imported or purchased. [7]
- An FDA Pharmacy Compounding Advisory Committee meeting in July 2026 recommended adding BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax to the Section 503A Bulk Drug Substances List, a nonbinding step that, if finalized through formal rulemaking, would open a path for licensed Arkansas pharmacies to compound some of these peptides legally. [1]
- More than 40 state attorneys general, a group that can include Arkansas, sent the FDA a 2025 letter describing enforcement concerns about research-use-only GLP-1 products sold to consumers without prescriptions, signaling a national enforcement trend rather than an Arkansas-specific action. [8]
Peptide-by-peptide status in Arkansas
| BPC-157 | BPC-157 is not FDA-approved and is treated as an unapproved research chemical in Arkansas, meaning no Arkansas pharmacy or prescriber can lawfully sell or dispense it for human use under current rules, though a 2026 FDA advisory panel recommendation could eventually allow licensed compounding. [1] |
|---|---|
| Semaglutide / Tirzepatide (GLP-1 class) | FDA-approved semaglutide and tirzepatide products (e.g., Ozempic, Wegovy, Zepbound) are legal in Arkansas by prescription only, while compounded versions are legal only when a licensed Arkansas 503A pharmacy or 503B outsourcing facility meets federal copy, ingredient, and shortage-status requirements alongside state compounding rules. [9] |
| TB-500 | TB-500 is an unapproved peptide in Arkansas with no FDA-approved human drug status, placing it in the same 'unlawful for general sale or human-use marketing' category as BPC-157, subject to a pending 2026 FDA advisory recommendation for possible future 503A compounding eligibility. [1] |
| Human Growth Hormone (HGH/somatropin) | HGH is a federally controlled prescription drug in Arkansas that can only be lawfully dispensed by a licensed pharmacy pursuant to a valid prescription from an authorized practitioner, consistent with Arkansas's general requirement that prescription drugs be compounded or dispensed only by licensed pharmacists. [4] |
Sources
Last researched: 2026-10-02
Frequently asked questions
Can I buy peptides like BPC-157 in Arkansas without a prescription?
No -- BPC-157 is an unapproved drug under federal law, so it cannot be legally sold over the counter or prescribed anywhere, including Arkansas, regardless of how it is marketed online. [2]
Is it legal to import research peptides into Arkansas for personal use?
Buying 'research-use-only' peptides for personal self-administration occupies a legal gray area in Arkansas as elsewhere in the U.S.; selling such peptides for human consumption is illegal under federal law even though enforcement has historically focused more on sellers than individual buyers. [7]
Can a telehealth provider legally prescribe compounded semaglutide in Arkansas?
A telehealth provider can prescribe compounded semaglutide in Arkansas only if a valid patient-specific prescription is paired with sourcing from a properly licensed 503A pharmacy or 503B outsourcing facility that meets both federal copy-compounding rules and Arkansas Board of Pharmacy compounding standards. [9]
What happens if a pharmacy or clinic in Arkansas is caught selling unapproved peptides for human use?
Arkansas pharmacies and prescribers risk state licensure action under Board of Pharmacy compounding and pharmacist-licensing rules, on top of a national trend of state attorneys general and federal enforcement increasingly targeting sellers and clinics that market unapproved research-grade peptides for human injection. [8]
Will BPC-157 or TB-500 become legal prescription peptides in Arkansas soon?
Possibly in the future -- an FDA advisory committee recommended in July 2026 that BPC-157, TB-500, and four other peptides be added to the 503A Bulk Drug Substances List, but this is only a nonbinding recommendation and formal FDA rulemaking (which can take months) must still occur before Arkansas pharmacies could compound them legally. [1]